Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021
- 30 August 2021
- journal article
- editorial
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 27, e934514
- https://doi.org/10.12659/msm.934514
Abstract
#934514 - Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021 - Full ViewThis publication has 12 references indexed in Scilit:
- Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating CircumstancesJAMA, 2021
- How COVID-19 has fundamentally changed clinical research in global healthThe Lancet. Global Health, 2021
- Trends in Oncology Clinical Trials Launched Before and During the COVID-19 PandemicJAMA Network Open, 2021
- Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19JAMA, 2020
- Implications for Design and Analyses of Oncology Clinical Trials During the COVID-19 PandemicJAMA Oncology, 2020
- The impact of the global COVID‐19 pandemic on the conduct of clinical trials: Return to normalcy by considering the practical impact of a structured ethical analysisBritish Journal of Clinical Pharmacology, 2020
- Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemicBMC Medical Ethics, 2017
- SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical TrialsAnnals of Internal Medicine, 2013
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised TrialsPLoS Medicine, 2010
- Guidance for Developers of Health Research Reporting GuidelinesPLoS Medicine, 2010